表: 评估随访时, 一般资料, 临床信息和基线血红蛋白在三组患者中是否存在差异的结果 (单因素分析)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | Total (n = 101) | Hb上升组 (n = 55) | Hb下降组 (n = 23) | Hb不变组 (n = 23) | p | statistic |
| 年龄, Median (Q1,Q3) | 67 (58, 76) | 65 (55.5, 76) | 66 (59, 72.5) | 70 (65.5, 77) | 0.221 | 3.022 |
| 性别, n (%) |  |  |  |  | 0.153 | 3.75 |
| 女 | 68 (67) | 36 (65) | 13 (57) | 19 (83) |  |  |
| 男 | 33 (33) | 19 (35) | 10 (43) | 4 (17) |  |  |
| bmi, Median (Q1,Q3) | 20.7 (18.37, 22.95) | 20.86 (18.62, 23.1) | 20.42 (16.8, 22.67) | 19.84 (17.07, 21.99) | 0.287 | 2.5 |
| 化疗有无, n (%) |  |  |  |  | 0.597 | Fisher |
| 无 | 12 (12) | 5 (9) | 3 (13) | 4 (17) |  |  |
| 有 | 89 (88) | 50 (91) | 20 (87) | 19 (83) |  |  |
| kps, Median (Q1,Q3) | 80 (70, 90) | 80 (70, 90) | 80 (62.5, 90) | 80 (70, 90) | 0.569 | 1.128 |
| 确诊部位, n (%) |  |  |  |  | 0.018 | Fisher |
| 残胃癌 | 1 (1) | 0 (0) | 0 (0) | 1 (4) |  |  |
| 胃体 | 39 (39) | 23 (43) | 9 (39) | 7 (30) |  |  |
| 胃底 | 1 (1) | 0 (0) | 0 (0) | 1 (4) |  |  |
| 胃窦 | 29 (29) | 21 (39) | 5 (22) | 3 (13) |  |  |
| 贲门 | 30 (30) | 10 (19) | 9 (39) | 11 (48) |  |  |
| 病理类型, n (%) |  |  |  |  | 0.87 | Fisher |
| 不详 | 7 (7) | 3 (5) | 3 (13) | 1 (4) |  |  |
| 印戒细胞 | 2 (2) | 1 (2) | 0 (0) | 1 (4) |  |  |
| 印戒细胞癌 | 3 (3) | 3 (5) | 0 (0) | 0 (0) |  |  |
| 粘液细胞腺癌 | 1 (1) | 1 (2) | 0 (0) | 0 (0) |  |  |
| 腺癌 | 87 (86) | 46 (84) | 20 (87) | 21 (91) |  |  |
| 鳞癌 | 1 (1) | 1 (2) | 0 (0) | 0 (0) |  |  |
| 分化程度, n (%) |  |  |  |  | 0.427 | Fisher |
| 中低分化 | 18 (20) | 11 (22) | 3 (19) | 4 (18) |  |  |
| 中分化 | 21 (24) | 15 (29) | 1 (6) | 5 (23) |  |  |
| 低分化 | 48 (54) | 24 (47) | 12 (75) | 12 (55) |  |  |
| 高分化 | 2 (2) | 1 (2) | 0 (0) | 1 (5) |  |  |
| 用药时间, n (%) |  |  |  |  | < 0.001 | 29.513 |
| 大于三个月 | 72 (71) | 50 (91) | 7 (30) | 15 (65) |  |  |
| 小于三个月 | 29 (29) | 5 (9) | 16 (70) | 8 (35) |  |  |
| 基线是否贫血, n (%) |  |  |  |  | < 0.001 | 14.857 |
| 贫血组 | 54 (53) | 39 (71) | 8 (35) | 7 (30) |  |  |
| 非贫血组 | 47 (47) | 16 (29) | 15 (65) | 16 (70) |  |  |
| 血红蛋白, Median (Q1,Q3) | 100 (85, 116) | 91 (80.5, 102) | 125.6 (90.5, 152.35) | 115 (92, 117) | < 0.001 | 18.64 |

表: 评估随访时免疫指标的变化在三组患者中是否存在差异 (单因素分析)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | Total (n = 101) | Hb下降组 (n = 23) | Hb不变组 (n = 23) | Hb上升组 (n = 55) | p | Statistic |
| CD3差值, Median (Q1,Q3) | 0.02 (-0.1, 0.14) | -0.01 (-0.14, 0.07) | 0 (-0.09, 0.1) | 0.06 (-0.07, 0.18) | 0.218 | 3.048 |
| CD3CD4差值, Median (Q1,Q3) | 0 (-0.27, 0.14) | -0.02 (-0.3, 0.17) | -0.06 (-0.28, 0.1) | 0 (-0.24, 0.2) | 0.682 | 0.766 |
| CD3CD8差值, Median (Q1,Q3) | 0.01 (-0.27, 0.3) | 0.08 (-0.24, 0.25) | 0.12 (-0.16, 0.38) | 0 (-0.34, 0.32) | 0.787 | 0.479 |
| CD3CD4CD25.CD3CD4差值, Median (Q1,Q3) | 0.06 (-0.44, 0.44) | 0.05 (-0.42, 0.27) | 0 (-0.39, 0.4) | 0.11 (-0.44, 0.51) | 0.688 | 0.747 |
| CD3CD4CD25FoxP3.CD3CD4差值, Median (Q1,Q3) | 0.12 (-0.35, 0.55) | 0.42 (-0.03, 0.79) | 0.12 (-0.45, 0.46) | -0.1 (-0.38, 0.5) | 0.04 | 6.447 |
| CD3.CD19.差值, Median (Q1,Q3) | 0.04 (-0.35, 0.36) | -0.12 (-0.27, 0.3) | 0.01 (-0.61, 0.5) | 0.07 (-0.34, 0.37) | 0.79 | 0.471 |
| CD3.CD16.差值, Median (Q1,Q3) | 0.02 (-0.7, 0.7) | 0.18 (-0.42, 0.71) | -0.58 (-1.06, 0.33) | 0.02 (-0.7, 0.78) | 0.117 | 4.296 |
| CD4.CD8差值, Median (Q1,Q3) | -0.07 (-0.5, 0.26) | -0.08 (-0.61, 0.31) | -0.15 (-0.5, 0.19) | 0 (-0.46, 0.33) | 0.831 | 0.37 |

评注:

1) 这些指标在基线和随访的数据都是先通过自然对数转换, 而后再做差. 即log(随访数据) – log(基线数据) = log(随访数据/基线数据)

2) 这个p值是三组间只要任意一对存在差异, p值就会小于0.05. 举例说明, 假如hb下降组和hb不变组存在差异, 但是hb下降组和hb上上升组不存在差异, 在这种情况下, p值还是小于0.05. 因此, 需要进一步做组间比较, 这就是后面为何画了那么多组间比较的图来进一步展示组间差异.

表: 评估随访时实验室检查结果的变化在三组患者中是否存在差异 (单因素分析)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | Total (n = 101) | Hb下降组 (n = 23) | Hb不变组 (n = 23) | Hb上升组 (n = 55) | p | statistic |
| CRP差异, Median (Q1,Q3) | 0.24 (-1.17, 1.91) | 0.25 (-1.12, 1.32) | 1.1 (-0.33, 2.72) | 0.02 (-1.89, 1.33) | 0.138 | 3.967 |
| IL6差异, Median (Q1,Q3) | -0.17 (-1.17, 1.01) | -0.17 (-0.64, 1.06) | 0 (-0.91, 1.65) | -0.23 (-1.31, 0.71) | 0.422 | 1.727 |
| mcv差异, Median (Q1,Q3) | -0.2 (-6.7, 8.9) | 5.2 (-3.3, 12.55) | 0.3 (-5.9, 7.65) | -1.1 (-9.22, 6.05) | 0.34 | 2.159 |
| mch差异, Median (Q1,Q3) | 0.01 (-0.09, 0.09) | 0.03 (-0.08, 0.12) | -0.01 (-0.08, 0.08) | 0.01 (-0.08, 0.09) | 0.916 | 0.176 |
| mchc差异, Median (Q1,Q3) | -0.02 (-2.16, 0.02) | -0.03 (-0.07, 0.02) | -0.02 (-0.07, 0.01) | -0.02 (-2.19, 0.02) | 0.981 | 0.038 |
| 中性粒细胞绝对值差异, Median (Q1,Q3) | -0.04 (-0.68, 0.71) | -0.35 (-1.09, 0.24) | -0.04 (-0.37, 0.89) | 0.02 (-0.77, 0.82) | 0.185 | 3.377 |
| 淋巴细胞绝对值差异, Median (Q1,Q3) | -0.06 (-0.58, 0.49) | -0.5 (-1.07, -0.07) | 0.23 (-0.46, 0.49) | 0.07 (-0.35, 0.66) | 0.013 | 8.756 |
| 中性粒比淋巴差异, Median (Q1,Q3) | -0.05 (-0.78, 0.89) | 0.34 (-0.54, 0.64) | -0.26 (-0.73, 0.95) | -0.16 (-0.82, 0.88) | 0.904 | 0.201 |

评注事项与上一个表相同.































